Form 4: ADC Therapeutics CMO Sells Shares for Tax Obligations

ADC Therapeutics' Chief Medical Officer, Mohamed Zaki, disposed of 41,068 common shares at $3.29 each to satisfy tax withholding obligations.

Summary

• Mohamed Zaki, Chief Medical Officer of ADC Therapeutics SA (ADCT), reported a transaction involving common shares.
• On December 6, 2025, Zaki disposed of 41,068 common shares.
• The shares were disposed of at a price of $3.29 per share.
• This transaction was categorized as an 'F' transaction code, indicating shares withheld by the Issuer to satisfy tax withholding obligations.
• The tax obligations were in connection with the vesting of previously granted restricted share units.
• Following this transaction, Mohamed Zaki beneficially owns 421,820 common shares directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction for tax withholding purposes related to vested equity compensation. This type of transaction is neutral in sentiment as it does not reflect a discretionary decision by the insider to buy or sell based on their outlook for the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a tax withholding event related to equity compensation. It does not provide information relevant to broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related transaction and not a discretionary sale indicating a change in management's confidence.

Key Dates

Keywords

ADC Therapeutics, ADCT, Mohamed Zaki, Form 4, Insider Transaction, Tax Withholding, Restricted Share Units, CMO